Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera

Marina Panova-Noeva, Marina Marchetti, Henri Maria Spronk, Laura Russo, Erika Diani, Good Finazzi, Silvia Salmoiraghi, Aueesandrd Rambaldi, Titiano Barbui, Huao Ten Cate, Anna Falanga*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

64 Citations (Web of Science)

Abstract

The platelet contribution to the thrombophilic state of patients with myeloproliferative neoplasms (MPNs), i.e., essential thrombocythemia (ET) and polycythemia vera (PV), remains uncertain. In this study we aimed to characterize the thrombin generation (TG) potential expressed by platelets from these subjects, compare it to normal platelets, and identify what factors might be responsible for platelet TG. In a group of 140 MPN patients (80 ET and 60 PV) and 72 healthy subjects we measured the global procoagulant potential of platelet rich plasma (PRP) utilizing the TG assay by the calibrated automated thrombogram (CAT). To characterize the procoagulant contribution of platelets in PRP, the TG of both isolated platelets and platelet poor plasma was measured, and the platelet surface expression of TF was determined. Finally, the activation status of platelets was assessed by the levels of P-selectin expressed on platelet surface. MPN patients had significantly increased PRP and isolated platelet TG potential compared to controls. This was associated to the occurrence of platelet activation. Patients carriers of the JAK2V617F mutation showed the highest values of TG and platelet surface TF and P-selectin. Platelet TG potential was significantly lower in hydroxyurea (HU) compared to non-HU-treated patients and was lowest in HU-treated JAK2V617F carriers. In subjects not receiving HU, platelet TG significantly increased by JAK2V617F allele burden increment (P <0.05). This study demonstrates a platelet-dependent form of hypercoagulability in MPN patients, particularly in those carriers of the JAK2V617F mutation. The cytoreductive therapy with HU significantly affects this prothrombotic phenotype. Am. J. Hematol. 86:337-342, 2011.
Original languageEnglish
Pages (from-to)337-342
JournalAmerican Journal of Hematology
Volume86
Issue number4
DOIs
Publication statusPublished - Apr 2011

Cite this